Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
- Resource Type
- Article
- Authors
- Zid, Yasmin; Robertson, Neil P.
- Source
- Journal of Neurology. Apr2024, Vol. 271 Issue 4, p2141-2143. 3p.
- Subject
- *NATALIZUMAB
*JOHN Cunningham virus
*MULTIPLE sclerosis
*PROGRESSIVE multifocal leukoencephalopathy
- Language
- ISSN
- 0340-5354
Recent studies have explored extended interval dosing (EID) strategies for high-efficacy disease-modifying therapies in multiple sclerosis (MS), specifically focusing on natalizumab and ocrelizumab. These studies suggest that EID may reduce treatment burden and associated risks without compromising therapeutic efficacy. However, there are limitations to these studies, such as small sample sizes and short follow-up durations. Further research in larger cohorts with longer follow-up periods is needed to validate these findings and optimize care for MS patients. [Extracted from the article]